Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label study assessing the safety and efficacy of naltrexone sustained release (SR)/bupropion sustained release (SR) in overweight or obese subjects with major depression.

Next Previous
Search
Trial Profile

An open-label study assessing the safety and efficacy of naltrexone sustained release (SR)/bupropion sustained release (SR) in overweight or obese subjects with major depression.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naltrexone/bupropion (Primary)
  • Indications Major depressive disorder; Obesity
  • Focus Therapeutic Use
  • Sponsors Orexigen Therapeutics [CEASED]

    • Most Recent Events

    • 16 Sep 2017 Results of post-hoc analysis assessing relationship between change BES score and change in depression score published in the Advances in Therapy
    • 07 Dec 2010 Naltrexone/bupropion has received a positive recommendation from the FDA Advisory Committee for the treatment of obesity, as reported in an Orexigen Therapeutics and Takeda Pharmaceutical Company media release
    • 26 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association, according to a Orexigen Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top